Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-γ and decrease in TGF-β1

International Heart Journal

Volumn 48, Issue 5, 2007, Pages 637-647

  Takahashi, Toshiaki ^a   Ono, Hidehiko ^a   Ono, Yuko ^a   Ishimitsu, Toshihiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone antagonists; Angiotensin II type 1 receptor blockers; Hypertension; Nephrosclerosis; Peroxisome proliferator activated receptors; Transforming growth factor beta

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SPIRONOLACTONE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; CELL INFILTRATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; GENE EXPRESSION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY PARENCHYMA; LOW DRUG DOSE; MALE; MALIGNANT HYPERTENSION; MONOTHERAPY; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; SCORING SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; URINARY EXCRETION;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HYPERTENSION, MALIGNANT; MALE; NEPHROSCLEROSIS; NG-NITROARGININE METHYL ESTER; PPAR GAMMA; RATS; RATS, INBRED SHR; RNA, MESSENGER; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 36749006016     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.637     Document Type: Article

References (40)

1. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-91.
2. Brenner BM, Cooper ME, de Zeeuw D, et al. RENNAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
3. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats: Systemic, renal, and glomerular hemodynamics. Hypertension 1995; 26: 249-55.
4. Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED. Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 2001; 38: 1300-6.
5. Ono H, Saitoh M, Ono Y, Ishimitsu T, Matsuoka, H. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats. J Hypertens 2004; 22: 1389-95.
6. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996; 27: 176-83.
7. Nakamura Y, Ono H, Zhou Y, Frohlich ED. Angiotensin type 1 receptor antagonisur and ACE inhibition produce similar renoprotection in N (omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001; 37: 1262-7.
8. Sato A, Hayashi Y, Naruse K Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-8.
9. Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
10. Rocha, R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-8.
11. Quan ZY, Walster M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-33.
12. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
13. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPAR ganum) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614-9.
14. Diep QN, Amiri F, Benkirane Y, Paradis P, Schiffirin EL. Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 2004; 82: 976-85.
15. Pechanova O, Matuskova J, Capikova D, Jendekova L, Paulis L, Slinko F. Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats. Kidney Int 2006; 70: 170-6.
16. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20: 205-21.
17. Bohm M, Lee M, Kreutz R, et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13: 891-9.
18. Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998; 31: 795-801.
19. Zhou X, Ono H, Ono Y, Frohlich ED. N- and L-type calcium channel antagonist improves glomerular dynamics reverses severe nephroseterosis, and inhibits apdptosis and proliferation in an I-NAME/SHR model. J Hypertens 2002; 20: 993-1000.
20. Watanabe S, Ono H, Ishimitsu T, Matsuoka H, Ono Y, Fujimori T. Calcium antagonist inhibits glomerular cell apoptosis and injuries of L-NAME exacerbated nephrosclerosis in SHR. Hypertens Res 2000; 23: 683-91.
21. Inada H, Ono H, Minami J, Ishimitsu. T, Mastuoka H. Nipradilol prevents LNAME-exacerbated nephrosclerosis with decreasing of caspase-3 expression in SHR. Hypertens Res 2002; 25: 433-40.
22. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
23. Duncan WG. Multiple range and multiple F test. Biometrics 1995; 11: 1-42.
24. Wolf G. Angiotensin II as a mediator of tabulointerstitial injury. Nephrol Dial Transplant 2000; 15: 61-3. (Review)
25. Luft FC. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 2002; 11: 59-66. (Review)
26. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286: F1059-62.
27. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003; 14: 2395-401. (Review)
28. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116:263-72. (Review)
29. Blasi ER, Rocha R, Rudolph AE, Biomme EA, Polly ML, McMahon EG. Aldosterorie/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-800.
30. Ishimitsu T, Kameda T, Akashiba A, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005; 28: 865-70.
31. Okada T, Nagai M, Taniguchi I, et al. Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats. Int Heart J 2006; 47: 783-93.
32. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-302.
33. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-8.
34. Derosa G, Cicero AF, Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-24.
35. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press 2006; 15: 135-50. (Review)
36. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 2004; 43: 993-1002.
37. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial influction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
38. Dabek J, Kulach A, Monastyrska-Cup B, Gasior Z. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'. Pharmacol Rep 2006; 58: 799-805. (Review)
39. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E. Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74: 196-206.
40. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats, through anti-inflammatory effects mediated by inhibition of NF-kappa B activation. Am J Physiol Renal Physiol 2007; 292: F1141-50.